Two of the main processes that hinder spinal cord repair after injury are scar-tissue formation and lack of axon growth, and microtubule formation is a key component of both. Hellal et al. therefore investigated whether Taxol, a microtubule-stabilising drug that is widely used in cancer therapy to limit cell division, could reduce these effects following spinal cord injury (SCI). In rats, application of a low dose of Taxol at the site of SCI interfered with mechanisms important for scar formation, such as TGFβ signalling, transduction of which requires the microtubule network. In addition to decreasing scar formation, Taxol treatment reduced the amount of growth-inhibitory chondroitin sulfate proteoglycans at the lesion site, which together created an environment conducive to axon growth. Moreover, Taxol treatment induced axon regeneration, resulting in functional improvement. By targeting the cytoskeleton, at which growth inhibitory signals converge, rather than interfering with single inhibitory factors, Taxol could provide multi-targeted therapy for SCI, and has the advantage of being an approved drug. Future research will aim to discover whether regeneration is seen when the time between injury and treatment is increased.
Cancer drug promotes axon regeneration
Cancer drug promotes axon regeneration. Dis Model Mech 1 March 2011; 4 (2): 136. doi:
Download citation file:
Advertisement
Cited by
Call for Papers – Infectious Disease: Evolution, Mechanisms and Global Health
Showcase your latest research on our upcoming Special Issue: Infectious Disease: Evolution, Mechanisms and Global Health. This issue will be coordinated by DMM Editors Sumana Sanyal and David Tobin alongside Guest Editors Judi Allen and Russell Vance. The deadline for submitting articles to this Special Issue has been extended to Monday 24 February 2025.
Biologists @ 100 - join us in Liverpool in March 2025
We are excited to invite you to a unique scientific conference, celebrating the 100-year anniversary of The Company of Biologists, and bringing together our different communities. The conference will incorporate a DMM programme on antimicrobial resistance on 26 March 2025. Find out more and register to join us in March 2025 in Liverpool, UK. The final deadline to register is 28 February 2025.
It's about time: the heterochronic background for the 2024 Nobel Prize in Physiology or Medicine
In this Editorial, Bruce Wightman writes about the groundwork laid by investigating the timing of developmental events in nematodes which led to the 2024 Nobel Prize in Physiology or Medicine.
Read & Publish Open Access publishing: what authors say
We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
Other journals from
The Company of Biologists